arXiv:2212.00223 공식 코드 · Papers with Code

Biomedical NER for the Enterprise with Distillated BERN2 and the Kazu Framework

Wonjin Yoon, Richard Jackson, Elliot Ford, Vladimir Poroshin, Jaewoo Kang

제출 2022-12-01

원문 초록

In order to assist the drug discovery/development process, pharmaceutical companies often apply biomedical NER and linking techniques over internal and public corpora. Decades of study of the field of BioNLP has produced a plethora of algorithms, systems and datasets. However, our experience has been that no single open source system meets all the requirements of a modern pharmaceutical company. In this work, we describe these requirements according to our experience of the industry, and present Kazu, a highly extensible, scalable open source framework designed to support BioNLP for the pharmaceutical sector. Kazu is a built around a computationally efficient version of the BERN2 NER model (TinyBERN2), and subsequently wraps several other BioNLP technologies into one coherent system. KAZU framework is open-sourced: https://github.com/AstraZeneca/KAZU

함께 살펴볼 논문

공통 태그를 근거로 연결했습니다. 실제 인용 관계나 논문의 우수성을 뜻하지 않습니다.

토론

이 논문과 연결된 포럼 글이 아직 없습니다.